Compile Data Set for Download or QSAR
Report error Found 174 Enz. Inhib. hit(s) with all data for entry = 9922
TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499388(4-((3-(5- (cyclopropylmethyl)isoxazol-3- yl)phenox...)
Affinity DataIC50: 50nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499334(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)phenox...)
Affinity DataIC50: 50nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499324(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)phenox...)
Affinity DataIC50: 50nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499334(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)phenox...)
Affinity DataIC50: 50nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499313(4-((3-(6- (cydopropylmethoxy)pyridin-3- yl)phenoxy...)
Affinity DataIC50: 80nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499312(N-(methylsulfonyl)-4-((3-(6- ((tetrahydro-2H-pyran...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499313(4-((3-(6- (cydopropylmethoxy)pyridin-3- yl)phenoxy...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499314(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)phenox...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499315(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)phenox...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499316(4-((3-(6-((3,3- difluorocyclobutyl)methoxy) pyridi...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499317(4-((3-(6-((4,4- difluorocyclohexyl)methoxy) pyridi...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499318(4-((3-(6-(cyclopropylmethoxy)-4- methylpyridin-3- ...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499319(4-((3-(6- (cyclopentylmethoxy)pyridin-3- yl)phenox...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499320(4-((3-(6-(cyclopropylmethoxy)- 5-methylpyridin-3- ...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499321(tert-butyl 4-(((5-(3-((4- ((methylsulfonyl)carbamo...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499322(4-((2-chloro-5-(6- (cyclopropylmethoxy)pyridin-3- ...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499323(3-chloro-4-((3-(6- (cyclopropylmethoxy)pyridin-3- ...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499324(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)phenox...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499325(4-((3-(6- (cyclobutylmethoxy)pyridin-3- yl)phenoxy...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499326(5-chloro-4-((3-(6- (cyclopropylmethoxy)pyridin-3- ...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499327(5-chloro-4-((3-(6- (cyclopropylmethoxy)pyridin-3- ...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499328(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)phenox...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499329(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)phenox...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499330(5-chloro-4-((3-(6- (cyclopropylmethoxy)pyridin-3- ...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499331(4-((3-chloro-5-(6- (cyclopropylmethoxy)pyridin-3- ...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499332(4-((4-chloro-3-(6- (cyclopropylmethoxy)pyridin-3- ...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499333(5-cyclopropyl-4-((3-(6- (cyclopropylmethoxy)pyridi...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499334(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)phenox...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499335(3-fluoro-N-(methylsulfonyl)-4- ((3-(6-((tetrahydro...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499336(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)phenox...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499337(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)phenox...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499338(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)phenox...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499339(N-(cyclopropylsulfonyl)-4-((3- (6-((tetrahydro-2H-...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499340(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)-5-flu...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499341(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)-5-flu...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499342(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)-5-flu...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499343(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)-5-flu...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499344(4-((3-cyclopropyl-5-(6- (cyclopropylmethoxy)pyridi...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499345(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)-5-met...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499346(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)-5-met...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499347(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)-5-(tr...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499348(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)-2-flu...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499349(3-cyano-4-((3-(6- (cyclopropylmethoxy)pyridin-3- y...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499350(3-cyano-4-((3-(6- (cyclopropylmethoxy)pyridin-3- y...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499351(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)-4-flu...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499352(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)-4-flu...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499353(4-((5-(6- (cyclopropylmethoxy)pyridin-3- yl)-2-flu...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499354(4-((3-bromo-5-(6- (cyclopropylmethoxy)pyridin-3- y...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499355(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)-4-flu...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499356(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)-4-flu...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 174 total ) | Next | Last >>
Jump to: